As a regulator of TRAF6/IKK in addition to MAPK[42], the efficacy of ASK1 drugs against NAFLD is still unclear in some clinical studies [43,44] . The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatotic liver disease.